Organisation paid for research Program year 2025 Source: CMS Open Payments

Biogenix Molecular

Neither a doctor nor a teaching hospital

Research payments

$877,990

4 payments

Through program year 2025, Biogenix Molecular is reported as receiving $877,990 in research payments, across 4 payments.

By program year

2 rows

Year	Kind	Amount	Payments
2025	Research	$812,754	3
2024	Research	$65,236	1

Breakdown

Who paid Research payments · program years 2024–2025

AstraZeneca Pharmaceuticals LP $696,213 2 payments
E.R. Squibb & Sons, L.L.C. $181,777 2 payments

Studies the money was for Research payments · program years 2024–2025

a phase I,first in human,dose escalation study of 225ac AZD2284 in patients with metastatic castration resistant prostate cancer $696,213 2 payments
Phase 1b/3 Global, Randomized, Controlled, Open-label Trial Comparing Treatment With RYZ101 to Standard of Care Therapy in Subjects With Inoperable, Advanced, SSTR+, Well-differentiated GEP-NETs That Have Progressed Following Prior 177Lu-SSA Therapy $181,777 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.